Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)
Phase of Trial: Phase II
Latest Information Update: 05 May 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IRENE; IRENE-study - NVALT16
- 02 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 02 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
- 14 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.